Early High-volume Continuous Veno-venous Hemofiltration for Patients With Severe Acute Pancreatitis (EHVCVVHSAP)

Air Force Military Medical University of People's Liberation Army

Status: Unknown

Conditions: Acute Pancreatitis

Treatments: Device: AN69 hemofilter; Other: conventional treatments

Study type: Interventional

Funder types: Other

Identifiers

NCT01595672

81170432 (Other Grant/Funding Number)

SAP-CVVH-XHDD-002

Details and patient eligibility

About

The purpose of this study is to determine the effect and safety of early high-volume continuous veno-venous hemofiltration for patients with severe acute pancreatitis.

Full description

The investigators anticipated that early high-volume continuous veno-venous hemofiltration (EHVCVVH) would result in a decrease of the composite of persistent organ failure or death by eliminating inflammatory mediators in blood. This study is designed to evaluate the impact of EHVCVVH on patients with severe acute pancreatitis.

Enrollment: 56 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• clinical diagnosis of severe acute pancreatitis
• written informed consent
• Time from onset of abdominal pain to admission ≤ 72 hours
• SIRS score ≥ 2

Exclusion criteria

• confirmed infection
• pregnancy
• patients needing emergency operation for abdominal compartment syndrome
• chronic renal diseases needing blood purification
• previous exploratory laparotomy for acute abdomen and diagnosis of pancreatitis during laparotomy
• acute flare-up of chronic pancreatitis
• malignancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

56 participants in 2 patient groups

EHVCVVH group

Active Comparator group

Description:

Patients receive conventional treatments recommended by guidelines with adjunctive early high-volume continuous veno-venous hemofiltration (EHVCVVH).

Treatment:

Device: AN69 hemofilter

Control group

Active Comparator group

Description:

Patients receive conventional treatments recommended by guidelines only.

Treatment:

Other: conventional treatments